Stockscreener 앱 받기
1.4375
1.38%
-0.0125
전일 마감가:
$1.45
열려 있는:
$1.45
하루 거래량:
1,941
Relative Volume:
0.01
시가총액:
$44.61M
수익:
$81,000
순이익/손실:
$-41.04M
주가수익비율:
-1.0916
EPS:
-1.3169
순현금흐름:
$-30.69M
1주 성능:
+3.62%
1개월 성능:
+6.72%
6개월 성능:
-15.38%
1년 성능:
+17.21%
1일 변동 폭
$1.43
$1.47
1주일 범위
$1.33
$1.54
52주 변동 폭
$1.06
$2.41
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
명칭
Actinium Pharmaceuticals Inc
전화
646-767-3870
주소
275 Madison Avenue, 7th Floor, New York, NY
ATNM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.43 | 45.23M | 81,000 | -41.04M | -30.69M | -1.3169 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.19 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.07 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.05 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
914.87 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.12 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-07 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-02-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-09-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-08-25 | 개시 | B. Riley Securities | Buy |
| 2020-11-05 | 개시 | Alliance Global Partners | Buy |
| 2017-12-06 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-10-23 | 재개 | ROTH Capital | Buy |
| 2017-09-14 | 개시 | Maxim Group | Buy |
| 2016-08-25 | 개시 | ROTH Capital | Buy |
| 2016-02-29 | 개시 | H.C. Wainwright | Buy |
| 2015-10-15 | 개시 | FBR Capital | Outperform |
| 2014-10-01 | 개시 | MLV & Co | Buy |
| 2014-07-22 | 개시 | Canaccord Genuity | Buy |
모두보기
Actinium Pharmaceuticals Inc 주식(ATNM)의 최신 뉴스
Will Actinium Pharmaceuticals Inc. (Delaware) stock gain from lower interest ratesJuly 2025 Highlights & Risk Controlled Stock Alerts - Newser
Why analysts recommend Actinium Pharmaceuticals Inc. (Delaware) stock2025 Earnings Surprises & Daily Entry Point Trade Alerts - Newser
How Actinium Pharmaceuticals Inc. (Delaware) stock expands through international markets2025 Short Interest & Real-Time Chart Pattern Alerts - Newser
Will Actinium Pharmaceuticals Inc. (Delaware) stock beat Nasdaq index returnsChart Signals & Consistent Profit Alerts - Newser
Can Actinium Pharmaceuticals Inc. (7AY1) stock double in coming yearsWeekly Stock Report & Short-Term High Return Ideas - Newser
Why hedge funds are buying Actinium Pharmaceuticals Inc. stockMarket Activity Report & Real-Time Volume Spike Alerts - Newser
Is Actinium Pharmaceuticals Inc. (7AY1) stock a momentum leaderJuly 2025 Volume & Fast Gain Swing Trade Alerts - Newser
Why Actinium Pharmaceuticals Inc. stock is a value investor pick2025 Market WrapUp & Expert Approved Trade Ideas - Newser
Jeri Kim: Thrilled to Join Actinium Pharmaceuticals as VP, Head of Solid Tumor Clinical Development - Oncodaily
Will Actinium Pharmaceuticals Inc. stock benefit from green energy trendsJobs Report & Daily Entry Point Alerts - Newser
Why retail traders accumulate Actinium Pharmaceuticals Inc. (Delaware) stockJuly 2025 Review & Real-Time Chart Breakout Alerts - Newser
How Actinium Pharmaceuticals Inc. (7AY1) stock valuation compares with sectorQuarterly Portfolio Summary & Weekly High Potential Alerts - Newser
How cyclical is Actinium Pharmaceuticals Inc. (7AY1) stock compared to rivalsJuly 2025 Volume & Smart Investment Allocation Insights - Newser
Actinium’s ATNM-400 shows efficacy in resistant breast cancers By Investing.com - Investing.com Nigeria
Actinium Pharmaceuticals (ATNM) Unveils Promising Preclinical Da - GuruFocus
Actinium's ATNM-400 shows strong efficacy in TNBC, beats therapy resistance at SABCS - marketscreener.com
Actinium’s ATNM-400 shows efficacy in resistant breast cancers - Investing.com
Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposiu - PR Newswire
Securities Fraud Class Action Filed Against Actinium Pharmaceutic - The National Law Review
Decliners Report: Will Actinium Pharmaceuticals Inc. stock outperform value stocksCPI Data & Safe Swing Trade Setup Alerts - BỘ NỘI VỤ
Will Actinium Pharmaceuticals Inc. stock outperform Dow Jones index2025 Market Overview & Precise Entry and Exit Recommendations - BỘ NỘI VỤ
Bull Bear: Can Actinium Pharmaceuticals Inc. stock continue upward trend2025 Retail Activity & AI Enhanced Trading Alerts - moha.gov.vn
Actinium Pharmaceuticals elects directors and approves proposals at annual meeting - Investing.com Nigeria
Actinium Pharmaceuticals elects directors and approves proposals at annual meeting By Investing.com - Investing.com South Africa
Actinium Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Actinium ATNM holders back board, 3-year say-on-pay cycle - Stock Titan
Why institutional investors increase stakes in Actinium Pharmaceuticals Inc. (7AY1) stock - newser.com
Is Actinium Pharmaceuticals Inc. (Delaware) stock a fit for income portfoliosJuly 2025 Catalysts & Advanced Technical Signal Analysis - newser.com
How Actinium Pharmaceuticals Inc. stock benefits from global expansionMarket Trend Report & Reliable Entry Point Alerts - newser.com
HC Wainwright Has Bullish Outlook for ATNM FY2025 Earnings - Defense World
How Actinium Pharmaceuticals Inc. (Delaware) stock responds to bond marketDollar Strength & AI Powered Market Entry Ideas - newser.com
What is the fair value estimate for Actinium Pharmaceuticals Inc. (7AY1) stock in 20252025 Winners & Losers & Verified Technical Signals - newser.com
Is Actinium Pharmaceuticals Inc. (7AY1) stock attractive for dividend growthJuly 2025 Volume & Fast Exit and Entry Strategy Plans - newser.com
Will Actinium Pharmaceuticals Inc. (Delaware) stock extend growth storyGDP Growth & Stepwise Trade Execution Plans - newser.com
Actinium Pharmaceuticals Inc (ATNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
1.57%
자본화:
|
볼륨(24시간):